MENU 简体中文ENG
Insights
Insights
Press Releases
May 13,2022
OBiO Technology to Present Data on OVersatile™ Platform for Process Development of Herpes Simplex Virus and Vaccinia Virus Products at the 25th ASGCT Annual Meeting
OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', SSE:688238.SH), today announced that research on novel manufacturing technologies via its OVersatile™ platform will be presented at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual meeting on May 16-19, 2022 in Washington, D.C.
Mar 22,2022
OBiO Technology Goes Public on Shanghai Stock Exchange Today
SHANGHAI, March 22, 2022 /PRNewswire/ -- On March 22, 2022, OBiO Technology (Shanghai) Corp., Ltd. ("OBiO" or "the Company"), has completed its initial public offering ("IPO") process and started trading on the Shanghai Stock Exchange's Sci-Tech innovation board (SSE, code: 688238).
May 11,2021
OBiO Announces ASGCT 24th Annual Meeting Attendance
OBiO Biotechnology (Shanghai) Corp. Ltd., (“OBiO” or “the Company”), announced it will be attending the American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting to be held virtually from May 11-14, 2021.
ALL PRESS RELEASES
Upcoming Events
Knowledge Center
Laboratory Sciences
List of In-Stock Viral Vectors
Related Publications
Adeno-Associated Virus Guide
Lentivirus Guide
CDMO Solutions
CDMO Solutions at OBiO – Gene and Cell Therapy
CONTACT US
First Name*
Last Name*
Company*
Email*
Phone Number*
I'm interested in…
Questions or Comments
Code*
I AGREE*
By submitting this form I agree that OBiO may process my data in the manner described in OBiO’s Privacy Policy
We won’t share your information.
OBiO Technology (Shanghai) Corp., Ltd.
About Us
Laboratory Services
Insights
Innovations
Investor Relations
CDMO Solutions
Process Development
cGMP Manufacturing
Quality & Regulatory
Cold Chain Logistics
Privacy Policy
© 2022 OBiO Technology (Shanghai) Corp., Ltd. All Rights Reserved